"Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention"

NCT01023139 | Unknown

• 1 other identifier: c.2009.025
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 2

Brief Summary

There are few studies that look at sustained weight loss in the adolescent population. This study uses a multidisciplinary approach along with pharmacotherapy (use of Meridia)to motivate and establish behavior changes in adolescents (12-18yo) during the first phase of the study. The second phase will have those who have lost at least 5% BMI to be randomized into one of two groups. This first group will have no intervention and will be followed at 3 and 6 months to assess for weight loss maintenance. The second group will continue on with monthly behavior modifications and also be evaluated at 3 and 6 months. The hypothesis proposed is that, 1)there will be sustained weight loss at the end of one year in both arms as compared to baseline BMI, 2) and the arm with the behavioral therapy intervention will be more successful than no intervention at weight loss maintenance.

Conditions

Obesity

Keywords

Adolescent; Obesity; Pharmacotherapy; Sibutramine

Outcome Measures

Primary Outcomes (1)

• % change in BMI z score

  12 month

Secondary Outcomes (2)

• absolute weight change

  12 months

• waist circumference change

  12 month

Study Arms (2)

Standard of care (SOC)

NO INTERVENTION

No intervention following phase 1 of the study is done during this 2nd phase. Participants will have their height and weights examined at 3 month and 6 month following end of phase 1. During these two visits, they will receive counseling from the physician regarding food choices and exercise maintenance.

Continuing Behavioral Therapy (CoBT)

EXPERIMENTAL

This arm follows the end of the phase 1 which incorporates behavioral therapy, nutrition counseling and pharmacotherapy with Sibutramine while medically supervised. Participants randomized to this arm no longer receive medication and will receive behavioral therapy once a month and then evaluated at 3 months and six months for weight loss maintenance.

Behavioral: Sibutramine

Interventions

Sibutramine BEHAVIORAL

During phase 1, sibutramine is given to all participants, 10mg po q day. If they do not meet a change in BMI of at least 2.5%,then the dosage may be increased to 15mg po q day. The main intervention in the study during phase 1 and 2is the behavioral modification

Continuing Behavioral Therapy (CoBT)

Eligibility Criteria

• Age: 12 Years - 18 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Age: \> or = 12 and \< or = 18 years old at the time of screening
• BMI that is at least more than the U.S. weighted mean of the 95th percentile based on age and sex
• Willing to lose weight to meet and continue study medication for the 12 month treatment period even if he/she meets personal weight loss goal.
• Willing to not start any new weight loss products
• Males or non-pregnant females (pregnancy determined by self-report)
• Females of childbearing potential if practicing acceptable method of contraception

You may not qualify if:

• Weight loss ≥ 10 pounds in previous 3 months
• Active gastrointestinal disorders (except GERD) such as peptic ulcer disease, irritable bowel disease, and gallbladder condition (in last 3 months); inflammable bowel disease (Crohn's ulcerative colitis, celiac sprue)
• At least 2 out of 3 blood pressure readings either systolic or diastolic ≥ 95%ile for height and age or pulse ≥95 beats per minute at initial visit.
• Drug treated diabetes mellitus or drug treated hypertension
• Drugs and/or supplements administered for the first time or withdrawn during the past 6 months which have a significant impact on body weight or digestion (see Appendix D)
• Inability or unwillingness to comply with protocol requirements, i.e. considered to be unfit for study participation, or unable to swallow pills.
• Unwilling to avoid consumption of alcoholic beverages
• Smoking or has started a smoking cessation program within the past six months
• Previous treatment with prescription sibutramine (Meridia®)
• History of recurrent nephrolithiasis
• Major psychiatric or eating disorders (i.e., major depressive disorder, bipolar disorder, anorexia nervosa, bulimia or laxative abuse)
• Kidney, liver, or thyroid disorder
• Drugs that are contraindicated with concomitant use of sibutramine (Meridia®) within last 4 weeks (See Appendix E)
• Cardiovascular disease (including arrhythmias, heart failure or congenital heart defect
• History of bleeding problems, hemophilia

Sponsors & Collaborators

• Brooke Army Medical Center: lead
• 59th Medical Wing: collaborator

Study Sites (2)

Brooke Army Medical Center

San Antonio, Texas, 78234, United States

RECRUITING

Wilford Hall Medical Center

San Antonio, Texas, 78234, United States

RECRUITING

MeSH Terms

Conditions

Obesity

Interventions

sibutramine

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Jorge L Cabrera, MD, PhD

  Brooke Army Medical Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jorge L Cabrera, MD, Ph.D

CONTACT

210-916-0607; jorge.luis.cabrera@us.army.mil

Jeffrey R Livezey, MD

CONTACT

210-916-0615; jeffrey.livezey@us.army.mil

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: FED

Study Record Dates

• First Submitted: December 1, 2009
• First Posted: December 2, 2009
• Study Start: April 1, 2009
• Primary Completion: November 1, 2010
• Study Completion: March 1, 2011
• Last Updated: December 2, 2009

Record last verified: 2009-12

Locations

US (2)